I’m very pleased to join a great team with an outstanding technology that offers tremendous potential to allow patients and healthcare professionals to manage disease in real time. With the seed financing from existing shareholders and business angels, and the €2M EFRO grant, we are now able to accelerate the development and
commercialization of our unique POC device to market.
Read more about Enzyre.
Enzyre’s platform technology requires just a small volume of blood and is able to measure up to twelve reactions simultaneously with high sensitivity and specificity, that can be carried out at home, on the road or in a critical care setting, without any laboratory infrastructure. This has the potential for better disease management and to improve the lives of patients living with chronic conditions whilst reducing healthcare costs.
Enzyre, a spin-out from Radboud University Medical Center in The Netherlands, was set up by Guido Maertens and Waander van Heerde, to develop innovative point of care (POC) devices to measure biomarkers in complex solutions. POC diagnostic tools are crucial for cost reduction and offer the flexibility to allow disease management to move to personalized medicine in the home or critical care setting. Enzyre’s POC device aims to revolutionize the understanding and diagnosis of multiple
thrombotic and hemostatic disorders by providing a real-time picture of a patient’s blood coagulation status. The total market size for hemophilia is estimated at €12B per year. The €2M EFRO grant and the seed financing will enable Enzyre to further develop its Hemophilia Biochip and bring its first product
They also announce the appointment of Dirk Pollet as Chief Executive Officer, who states: "